StockData

Black Diamond Therapeutics vs Fennec Pharmaceuticals

BDTX and FENC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BDTX and FENC compare

Fennec Pharmaceuticals is the larger company, worth 5.8 times as much as Black Diamond Therapeutics ($476M against $82.7M).

Fennec Pharmaceuticals grew revenue faster over the last twelve months (77.8% versus −100% for Black Diamond Therapeutics).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBDTXFENC
Size and price
Market cap$82.7M$476M
Share price$1.44$13.58
Change, 1 year−64.1%72.8%
Change, 5 years−77.3%40.9%
Beta (5Y)2.121.89
Employees2135
StockData Score
Total score77
Valuation score1 (better)0
Growth score02 (better)
Performance score13 (better)
Health score5 (better)2
Dividend score00
Valuation
P/S–8.0×
P/B0.9× (better)11.2×
Fair value–$7.22
Margin of safety–−88.0%
Growth
Revenue growth (TTM)−100%77.8% (better)
Revenue growth, 5Y average–195%
Net income growth (TTM)−395%–
EPS growth (TTM)−422%–
Profitability
Operating margin–−1.9%
Net margin–−5.5%
Return on equity−37.2%−18.6% (better)
Financial health
Debt / equity0.00–
Interest coverage–−1.2×
Current ratio7.28 (better)5.85
Altman Z-score−4.126.06 (better)
Piotroski F-score7 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions61.0%46.5%
Held by insiders9.1%–
Insider net buying, 12 months–−$9.9M
Short interest, % of float9.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.